# Biomarker Development for Response Prediction by DNA Mutational Analysis

> **NCT01855061** · — · TERMINATED · sponsor: **P.O. Witteveen** · enrollment: 79 (actual)

## Conditions studied

- Neoplasm Metastasis

## Interventions

- **PROCEDURE:** Biopsy
- **PROCEDURE:** Blood samples
- **PROCEDURE:** Pharmacokinetics
- **PROCEDURE:** Midazolam clearance test

## Key facts

- **NCT ID:** NCT01855061
- **Lead sponsor:** P.O. Witteveen
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2011-05
- **Primary completion:** 2015-11
- **Final completion:** 2016-08
- **Target enrollment:** 79 (ACTUAL)
- **Last updated:** 2018-03-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01855061

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01855061, "Biomarker Development for Response Prediction by DNA Mutational Analysis". Retrieved via MORVS 2026-10-09 from https://api.morvs.ai/clinical/NCT01855061. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*